Paper168385
Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.
Arcamone F and 10 others. J Med Chem, 1975. Cited by 180 papers, by iCite.
Cite this record
ConductScience Library. Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. Papers, record 168385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/168385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoglycosides | Major topic |
| Antineoplastic Agents | Major topic |
| Daunorubicin | Major topic |
| Doxorubicin | Major topic |
| Animals | |
| Cells, Cultured | |
| HeLa Cells | |
| Heart Rate | |
| In Vitro Techniques | |
| Leukemia, Experimental | |
| Mice | |
| Moloney murine leukemia virus | |
| Sarcoma 180 | |
| Sarcoma Viruses, Murine | |
| Stereoisomerism |
Source PubMed
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 180 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38474678 | Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation. | Molecules | 2024 | https://conductscience.org/library/papers/38474678 | PubMed |
| 31511390 | Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors. | J Virol | 2019 | https://conductscience.org/library/papers/31511390 | PubMed |
| 24105928 | Synthesis of vicinal aminoalcohols by stereoselective aza-Wacker cyclizations: access to (-)-acosamine by redox relay. | Angew Chem Int Ed Engl | 2013 | https://conductscience.org/library/papers/24105928 | PubMed |
| 21705665 | TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer. | Oncologist | 2011 | https://conductscience.org/library/papers/21705665 | PubMed |
| 21375717 | Natural products for cancer chemotherapy. | Microb Biotechnol | 2011 | https://conductscience.org/library/papers/21375717 | PubMed |
| 20424853 | Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry. | Histochem Cell Biol | 2010 | https://conductscience.org/library/papers/20424853 | PubMed |
| 8070217 | Clinical pharmacokinetics of epirubicin. | Clin Pharmacokinet | 1994 | https://conductscience.org/library/papers/8070217 | PubMed |
| 7693418 | Epirubicin. Clinical pharmacology and dose-effect relationship. | Drugs | 1993 | https://conductscience.org/library/papers/7693418 | PubMed |
| 6595241 | Phase II study of epirubicin in advanced malignant melanoma. | Invest New Drugs | 1984 | https://conductscience.org/library/papers/6595241 | PubMed |
| 6590532 | Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6590532 | PubMed |
| 6584236 | A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6584236 | PubMed |
| 6583205 | 4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors. | J Cancer Res Clin Oncol | 1984 | https://conductscience.org/library/papers/6583205 | PubMed |
| 6579052 | Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors. | J Cancer Res Clin Oncol | 1983 | https://conductscience.org/library/papers/6579052 | PubMed |
| 6378238 | Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6378238 | PubMed |
| 3886588 | The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3886588 | PubMed |
| 3863718 | Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3863718 | PubMed |
| 3857219 | Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3857219 | PubMed |
| 3520474 | Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties. | Pharm Weekbl Sci | 1986 | https://conductscience.org/library/papers/3520474 | PubMed |
| 3472675 | Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3472675 | PubMed |
| 3463434 | Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3463434 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/168385
GET https://conductscience.org/api/papers/v1/168385/cited_by?page=2